New drug triggers rapid cell death in cancer models
BRD-810 inhibits the MCL1 protein and reactivates apoptosis in tumor cells, displaying therapeutic potential in animal models.
Funding
Support for this research was provided in part by National Cancer Institute grant 5R35CA242457.
Paper cited
Rauh U, et al. BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models. Nature Cancer. Online August 23, 2024. DOI: 10.1038/s43018-024-00814-0.